Literature DB >> 29112648

Cost of Care for the Initial Management of Ovarian Cancer.

Alexandra S Bercow1, Ling Chen, Sudeshna Chatterjee, Ana I Tergas, June Y Hou, William M Burke, Cande V Ananth, Alfred I Neugut, Dawn L Hershman, Jason D Wright.   

Abstract

OBJECTIVE: To examine the cost of care during the first year after a diagnosis of ovarian cancer, estimate the sources of cost, and explore the out-of-pocket costs.
METHODS: We performed a retrospective cohort study of women with ovarian cancer diagnosed from 2009 to 2012 who underwent both surgery and adjuvant chemotherapy using the Truven Health MarketScan database. This database is comprised of patients covered by commercial insurance sponsored by more than 100 employers in the United States. Medical expenditures, including physician reimbursement, for a 12-month period beginning on the date of surgery were estimated. All payments were examined, including out-of-pocket costs for patients. Payments were divided into expenditures for inpatient care, outpatient care (including chemotherapy), and outpatient drug costs. The 12-month treatment period was divided into three phases: surgery to 30 days (operative period), 1-6 months (adjuvant therapy), and 6-12 months after surgery. The primary outcome was the overall cost of care within the first year of diagnosis of ovarian cancer; secondary outcomes included assessment of factors associated with cost.
RESULTS: A total of 26,548 women with ovarian cancer who underwent surgery were identified. After exclusion of patients with incomplete insurance enrollment or coverage, those who did not undergo chemotherapy, and those with capitated plans, our cohort consisted of 5,031 women. The median total medical expenditures per patient during the first year after the index procedure were $93,632 (interquartile range $62,319-140,140). Inpatient services accounted for $30,708 (interquartile range $20,102-51,107; 37.8%) in expenditures, outpatient services $52,700 (interquartile range $31,210-83,206; 58.3%), and outpatient drug costs $1,814 (interquartile range $603-4,402; 3.8%). The median out-of-pocket expense was $2,988 (interquartile range $1,649-5,088). This included $1,509 (interquartile range $705-2,878) for outpatient services, $589 (interquartile range $3-1,715) for inpatient services, and $351 (interquartile range $149-656) for outpatient drug costs.
CONCLUSION: The average cost of care for women with ovarian cancer in the first year after surgery is approximately $100,000. Patients bear approximately 3% of these costs in the form of out-of-pocket expenses.

Entities:  

Mesh:

Year:  2017        PMID: 29112648      PMCID: PMC5709160          DOI: 10.1097/AOG.0000000000002317

Source DB:  PubMed          Journal:  Obstet Gynecol        ISSN: 0029-7844            Impact factor:   7.661


  13 in total

1.  The cost-effectiveness of opportunistic salpingectomy versus standard tubal ligation at the time of cesarean delivery for ovarian cancer risk reduction.

Authors:  Akila Subramaniam; Brett D Einerson; Christina T Blanchard; Britt K Erickson; Jeff Szychowski; Charles A Leath; Joseph R Biggio; Warner K Huh
Journal:  Gynecol Oncol       Date:  2018-11-23       Impact factor: 5.482

2.  Algorithm to Identify Incident Epithelial Ovarian Cancer Cases Using Claims Data.

Authors:  Sarah P Huepenbecker; Hui Zhao; Charlotte C Sun; Shuangshuang Fu; Weiguo He; Sharon H Giordano; Larissa A Meyer
Journal:  JCO Clin Cancer Inform       Date:  2022-03

3.  Impact of robotic surgery on patient flow and resource use intensity in ovarian cancer.

Authors:  Jeremie Abitbol; Beste Kucukyazici; Sonya Brin; Susie Lau; Shannon Salvador; Agnihotram V Ramanakumar; Roy Kessous; Liron Kogan; John D Fletcher; Valerie Pare-Miron; Gilbert Liu; Walter H Gotlieb
Journal:  J Robot Surg       Date:  2022-08-04

4.  Hormonally Active Contraceptives, Part II: Sociological, Environmental, and Economic Impact.

Authors:  William V Williams; Joel Brind; Laura Haynes; Michael D Manhart; Hanna Klaus; Angela Lanfranchi; Gerard Migeon; Michael Gaskins; Elvis I Šeman; Lester Ruppersberger; Kathleen M Raviele
Journal:  Linacre Q       Date:  2021-04-21

5.  Employment disruption among women with gynecologic cancers.

Authors:  Roni Nitecki; Shuangshuang Fu; Kirsten A Jorgensen; Lauren Gray; Carolyn Lefkowits; Benjamin D Smith; Larissa A Meyer; Alexander Melamed; Sharon H Giordano; Pedro T Ramirez; Jose Alejandro Rauh-Hain
Journal:  Int J Gynecol Cancer       Date:  2021-11-16       Impact factor: 4.661

Review 6.  The Out-of-Pocket Cost Burden of Cancer Care-A Systematic Literature Review.

Authors:  Nicolas Iragorri; Claire de Oliveira; Natalie Fitzgerald; Beverley Essue
Journal:  Curr Oncol       Date:  2021-03-15       Impact factor: 3.677

7.  Impact of implementation of an enhanced recovery program in gynecologic surgery on healthcare costs.

Authors:  Ross F Harrison; Yao Li; Alexis Guzman; Brandelyn Pitcher; Andrea Rodriguez-Restrepo; Katherine E Cain; Maria D Iniesta; Javier D Lasala; Pedro T Ramirez; Larissa A Meyer
Journal:  Am J Obstet Gynecol       Date:  2019-07-31       Impact factor: 8.661

8.  Cost-effectiveness of laparoscopic disease assessment in patients with newly diagnosed advanced ovarian cancer.

Authors:  Ross F Harrison; Scott B Cantor; Charlotte C Sun; Mariana Villanueva; Shannon N Westin; Nicole D Fleming; Iakovos Toumazis; Anil K Sood; Karen H Lu; Larissa A Meyer
Journal:  Gynecol Oncol       Date:  2021-01-31       Impact factor: 5.482

9.  Patient cost sharing during poly(adenosine diphosphate-ribose) polymerase inhibitor treatment in ovarian cancer.

Authors:  Ross F Harrison; Shuangshuang Fu; Charlotte C Sun; Hui Zhao; Karen H Lu; Sharon H Giordano; Larissa A Meyer
Journal:  Am J Obstet Gynecol       Date:  2021-02-04       Impact factor: 10.693

10.  Temporal trends of healthcare system use between symptomatic presentation and ovarian cancer diagnosis in the United States.

Authors:  Sarah P Huepenbecker; Charlotte C Sun; Shuangshuang Fu; Hui Zhao; Weiguo He; Kristin Primm; Sharon H Giordano; Larissa A Meyer
Journal:  Int J Gynecol Cancer       Date:  2022-07-04       Impact factor: 4.661

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.